Spero Therapeutics (SPRO) Total Current Liabilities (2016 - 2026)

Spero Therapeutics has reported Total Current Liabilities for 11 years, with the latest figure at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 81.17% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (down 81.17% YoY), and the FY2025 full-year result was $8.9 million, down 81.93% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $5.5 million, down from $8.9 million in the prior quarter.
• The five-year high for Total Current Liabilities was $69.2 million in Q1 2022, with the low at $5.5 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $28.4 million across 5 years, with a median of $23.0 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 289.57% — and 2025, when it plunged 81.93%.
• Spero Therapeutics' Total Current Liabilities stood at $21.6 million in 2022, then soared by 71.62% to $37.2 million in 2023, then surged by 32.09% to $49.1 million in 2024, then sank by 81.93% to $8.9 million in 2025, then plunged by 38.1% to $5.5 million in 2026.
• The last three Total Current Liabilities figures came in at $5.5 million (Q1 2026), $8.9 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.